While statin therapy [3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR) inhibitors] is primarily used for cardiovascular protection based on its anti-atherosclerotic and endothelial protection benefits [8–10], its pleiotropic effects on cystic kidney disease warrant exploration. Here, HMGCR is linked to cystic kidney disease.